DSW Inc (NYSE:DSW) had its price target lowered by Canaccord Genuity from $38.00 to $28.00 in a research report sent to investors on Thursday morning. The firm currently has a hold rating on the stock. DSW Inc. (NYSE:DSW) net profit margin is 6.40% and weekly performance is -24.98%. On last trading day company shares ended up $25.05. Analysts mean target price for the company is $29.82. DSW Inc. (NYSE:DSW distance from 50-day simple moving average (SMA50) is -26.89%.
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of ITT Educational Services, Inc. (NYSE:ESI)concerning possible violations of federal securities laws. The investigation is focused on the Company’s business, operations and financial performance. ITT Educational Services, Inc. (NYSE:ESI) shares fell -0.46% in last trading session and ended the day on $17.22. ESI Gross Margin is 54.00% and its return on assets is 9.30%. ITT Educational Services, Inc. (NYSE:ESI) quarterly performance is -44.51%.
On May 28, Aeropostale Inc (NYSE:ARO) rallied following the completion of earlier announced $150 million financing deal with Sycamore Partners. The deal will bail out the beleaguered teen apparel retailer by mitigating any chances of near term liquidity crisis. Aeropostale witnessed its cash reserves fall 83.5% year over year to $24.5 million as of May 3, 2014, that could have resulted in potential cash crunch. Aeropostale Inc (NYSE:ARO) shares moved down -1.51% in last trading session and was closed at $3.91, while trading in range of $3.89 – $4.04. Aeropostale Inc (NYSE:ARO) year to date (YTD) performance is -56.99%.
Clovis Oncology (NASDAQ:CLVS) announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company’s novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β). Data from the study were presented in an oral presentation by Professor Jean-Charles Soria at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. Clovis Oncology Inc (NASDAQ:CLVS) ended the last trading day at $51.21. Company weekly volatility is calculated as 8.20% and price to cash ratio as 5.72. Clovis Oncology Inc (NASDAQ:CLVS) showed a negative weekly performance of-11057%.
Pomerantz LLP is investigating claims on behalf of investors of Infoblox, Inc. (NYSE:BLOX). Such investors are advised to contact Robert S. Infoblox Inc (NYSE:BLOX) shares moved down -36.84% in last trading session and was closed at $12.96, while trading in range of $12.01 – $13.49. Infoblox Inc (NYSE:BLOX) year to date (YTD) performance is -60.75%.
Leave a Reply